Status:
RECRUITING
Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Antifibrinolytic Agents
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Tranexamic acid (TXA) is a widely used antifibrinolytic agent that can reduce postoperative blood loss and packed red blood cell transfusions during cardiac surgery. Previous (in-vivo) studies have me...
Eligibility Criteria
Inclusion
- Eligible patients:
- Over 18 years old
- Elective surgery
- Written informed consent
- Patient planned for aortocoronary artery bypass graft surgery, aortic valve replacement or mitral valve surgery (or a combination of these procedures)
- Normal renal function
- No previous intake of anticoagulants except acetylsalicylic acid in the preoperative period
Exclusion
- Impaired renal function (eGFR \< 30 ml/min.)
- History of seizure
- Pregnancy
- Inability to understand and sign the informed consent (e.g., language problems, dementia, psychological disorders)
Key Trial Info
Start Date :
December 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
322 Patients enrolled
Trial Details
Trial ID
NCT06128330
Start Date
December 15 2023
End Date
December 31 2026
Last Update
June 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dpt. Anesthesiology and pain Medicine
Bern, Switzerland, 3010